Abstract
Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment strategy of advanced non-small cell lung cancer (NSCLC) in first- and second-line setting improving the prognosis of these patients. However, the treatment landscape has been also drastically overturned with the advent of targeted therapies in oncogenic-addicted advanced NSCLC patients. Despite ICIs represent an active and new treatment option for a wide range of advanced NSCLC patients, the efficacy and the optimal place of ICI in the treatment strategy algorithm of oncogenic-addicted tumors remains still controversial, as only a minority of trials with ICI enrol oncogenic-addicted NSCLC patients previously treated with standard therapy. Therefore, there are still several open questions about ICI in oncogenic-driven NSCLC, such as the efficacy and toxicities, which need to be addressed before considering treatment with ICI as a standard approach in this population. It is in this framework, we provide a thorough overview on this currently controversial topic.
Original language | English |
---|---|
Pages (from-to) | 47-58 |
Number of pages | 12 |
Journal | Cancer Treatment Reviews |
Volume | 71 |
DOIs | |
Publication status | Published - Dec 2018 |
Keywords
- Immunotherapy
- EGFR
- ALK
- ROS1
- BRAF
- Advanced non-small cell lung cancer
- IMMUNE CHECKPOINT INHIBITORS
- DABRAFENIB PLUS TRAMETINIB
- LIGAND 1 EXPRESSION
- OPEN-LABEL
- PD-L1 EXPRESSION
- MOLECULAR CHARACTERISTICS
- 1ST-LINE TREATMENT
- ANTITUMOR-ACTIVITY
- HER2 MUTATION
- STAGE IV